Clinical trialNCT01283139CompletedPhase 2Interventional

A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

SponsorMedImmune LLCEnrollment834Systemic Lupus Erythematosus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gabor Illei, MD
MedImmune LLC
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

107 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aire, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Quilmes, Argentina
Research Site
San Miguel de Tucumán, Argentina

Brazil

Research Site
Curitiba, Brazil
Research Site
Goiânia, Brazil
Research Site
Juiz de Fora, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil

Bulgaria

Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria

Canada

Research Site
Québec, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada

Chile

Research Site
Osorno, Chile
Research Site
Santiago, Chile
Research Site
Viña del Mar, Chile

France

Research Site
Bordeaux, France
Research Site
Le Kremlin-Bicêtre, France
Research Site
Paris, France
Research Site
Strasbourg, France

Germany

Research Site
Berlin, Germany
Research Site
Cologne, Germany
Research Site
Dresden, Germany
Research Site
Frankfurt, Germany
Research Site
Kiel, Germany
Research Site
Leipzig, Germany
Research Site
Mainz, Germany
Research Site
Münster, Germany
Research Site
Regensburg, Germany
Research Site
Würzburg, Germany

Hungary

Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Miskolc, Hungary
Research Site
Zalaegerszeg, Hungary

India

Research Site
Bangalore, India
Research Site
Secunderabad, India

Italy

Research Site
Brescia, Italy

67 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sifalimumab 1,200 mgSifalimumab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2011
Primary completion: 14 Nov 2013
Completion: 17 Apr 2014
Last update posted: 19 Apr 2018
Registered enrollment: 834
Registry id: NCT01283139

Cross-registrations

EU-CTR / CTIS (EudraCT)2010-024069-30

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.